GlassScriptPhysician profile
Robert M Deleon
NPI 1023507324
$2,150.45
in general payments reported to CMS, 2019-2025
22 companies · $177 in 2025
The $177 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $703 · 2022: $465 · 2023: $657 · 2024: $149 · 2025: $177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $983.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $982.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $489.47 | 2021-2023 | Belbuca |
| Biodelivery Sciences International, INC. | $235.05 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $194.70 | 2022 | |
| Forte Bio-Pharma LLC | $187.06 | 2021-2024 | Prolate, Nalocet |
| Scilex Pharmaceuticals INC. | $185.76 | 2022-2023 | Ztlido |
| Vertex Pharmaceuticals Incorporated | $156.16 | 2025 | |
| Almatica Pharma LLC | $105.23 | 2021-2023 | Gralise |
| Horizon Therapeutics Plc | $94.78 | 2021-2022 | |
| Boston Scientific Corporation | $78.06 | 2021-2023 | Wavewriter Alpha Prime 16 |
| Abbott Laboratories | $69.44 | 2024-2025 | Eterna |
| Bioventus LLC | $45.83 | 2024 | Exogen Ultrasound Bone Healing System, Durolane |
| Hikma Pharmaceuticals USA | $37.87 | 2022 | |
| Redhill Biopharma INC. | $37.06 | 2021-2022 | |
| Valinor Pharma, LLC | $36.48 | 2023 | Movantik |
| Ibsa Pharma INC. | $34.06 | 2023 | Tirosint, Licart |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $30.75 | 2023 | Seglentis |
| Curonix LLC | $26.33 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Grt US Holding, INC. | $26.32 | 2021 | |
| Averitas Pharma INC. | $24.30 | 2023 | Qutenza |
| Lilly USA, LLC | $21.15 | 2021 | |
| Virtus Pharmaceuticals LLC | $19.26 | 2023 | Levorphanol Tartrate |
| Arbor Pharmaceuticals, INC. | $15.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Deleon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.